Data science is shaping our discovery and development efforts
We are using advanced data science and neuroinformatics to map drug targets to specific brain circuitry and corresponding behaviors.
Stay informed about our latest developments
- July 22, 2019 BlackThorn Therapeutics Announces Its Participation in the Reward Task Optimization Consortium (RTOC)
- June 13, 2019 BlackThorn Therapeutics Closes $76 Million Series B to Advance Targeted Therapeutics for Mental Health
- April 1, 2019 BlackThorn Therapeutics Announces Positive Phase 1 Results for Its Selective KOR Antagonist, BTRX-335140